About: Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
Creator	Wang, Hongwu He, Jun Liu, Xiangguo Cao, Min Li, Cui Pharmacology, Hepatic Li, Yuting Fu, Hui Miao, Jing Brown, Lindsay Cui, Huantian Liao, Cao Liao, Jiabao Song, Ruiwen Wen, Weibo Zhang, Zhaiyi
Source	PMC
abstract	Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.3389/fphar.2020.00858
has license	cc-by
sha1sum (hex)	5a13b3306b8e7d56855298ac975d929b7b288bc7
schema:url	https://doi.org/10.3389/fphar.2020.00858
resource representing a document's title	Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
has PubMed Central identifier	PMC7295953
schema:publication	Front Pharmacol
resource representing a document's body	covid:5a13b3306b8e7d56855298ac975d929b7b288bc7#body_text
is schema:about of	named entity 'METABOLOMIC' named entity 'EFFECT' named entity 'INTERLEUKIN ' named entity 'REDUCED' named entity 'EFFECTS' named entity 'ESTABLISHED' named entity 'REFLECTED' named entity 'METABOLIC DISORDERS' named entity 'CONCLUSION' named entity 'ANALYSIS' named entity 'METABOLOMICS' named entity 'MECHANISMS' covid:arg/5a13b3306b8e7d56855298ac975d929b7b288bc7 named entity 'Beijing' named entity 'control groups' named entity 'nuciferine' named entity 'energy metabolism' named entity 'linoleic acid' named entity 'cholesterol' named entity 'nuciferine' named entity 'LC-MS' named entity 'LCAT' named entity 'lipogenesis' named entity 'serum' named entity 'inflammation' named entity 'NAFLD' named entity 'TNF-a' named entity 'CYP3A4' named entity 'hepatocyte' named entity '0.01' named entity 'metabolites' named entity 'nuciferine' named entity '0.01' named entity 'oxidation' named entity 'conjugated linoleic acid' named entity 'p-value' named entity 'steatosis' named entity 'OPLS' named entity 'microvesicular steatosis' named entity 'lecithin cholesterol acyltransferase' named entity 'normal saline' named entity 'control group' named entity 'supernatant' named entity 'animal study' named entity 'serum' named entity 'hepatocytes' named entity 'control group' named entity 'PLA2' named entity 'Biotech' named entity 'paraffin wax' named entity 'serum' named entity 'LDL-C' named entity 'serum' named entity 'rat model' named entity 'Rattus norvegicus' named entity '0.01' named entity 'liquid chromatography-mass spectrometry' named entity 'China' named entity 'NAFLD' named entity 'metabolic processes' named entity 'HDL-C' named entity 'liver' named entity 'Nuciferine' named entity 'NAFLD' named entity 'hepatocytes' named entity 'oxidative stress' named entity 'Biological Engineering' named entity 'serum levels'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software